- $2.55bn
- $1.50bn
- $139.74m
Beam Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary
Beam Therapeutics falls after patient death in early trial
Brief: Beam Therapeutics Reports Third Quarter 2024 Financial Results And Progress Across Priority Programs
U.S. RESEARCH ROUNDUP- Autozone, Costco Wholesale, Walmart
U.S. RESEARCH ROUNDUP-Amgen, Atkore, Moneylion
Beam Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Beam Therapeutics Inc expected to post a loss of $1.13 a share - Earnings Preview
Brief: Beam Therapeutics Announces First Patient Dosed In The Phase 1/2 Study Of Beam-302
U.S. RESEARCH ROUNDUP- Adtran Holdings, McKesson, Waters Corp
U.S. RESEARCH ROUNDUP- Ally Financial, GE Vernova, Navient
U.S. RESEARCH ROUNDUP-Autozone, Constellation Energy, Sterling Infrastructure
Beam Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Beam Therapeutics Q4 EPS USD 1.73
Beam Therapeutics Inc expected to post a loss of $1.01 a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Beam Therapeutics, Lam Research, Vir Biotechnology
Brief: Beam Therapeutics Highlights Progress Across Base Editing Portfolio
Brief: Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board
Verve Therapeutics drops on $148 mln equity raise, share placement with Eli Lilly
Brief: Beam Therapeutics - Strong Balance Sheet Provides Anticipated Operating Runway Into Second Half 2026